Mark R. Fleisher

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease

William J. Sandborn, Brian G. Feagan, Richard N. Fedorak et al. · Gastroenterology · 2008 · 740 citations

Inflammation, Allergy, Autoimmune Disease +8

A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease

William J. Sandborn, Subrata Ghosh, Julián Panés et al. · Clinical Gastroenterology and Hepatology · 2014 · 295 citations

Inflammation, Chronic Inflammatory Diseases, Anti-inflammatory +9

Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease

Miguel Regueiro, John F. Valentine, Scott E. Plevy et al. · The American Journal of Gastroenterology · 2003 · 222 citations

Malignant Neoplasms Subsequent to Treatment of Inflammatory Bowel Disease With 6-Mercaptopurine

Burton I. Korelitz, Felice Mirsky, Mark R. Fleisher et al. · The American Journal of Gastroenterology · 1999 · 136 citations

Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

Laurent Peyrin‐Biroulet, Ailsa Hart, Peter Bossuyt et al. · ˜The œLancet. Gastroenterology & hepatology · 2021 · 89 citations · Full text

Inflammation, Anti-inflammatory, Immunology +7